Larimar Therapeutics (LRMR) Amortizatization of Intangibles (2015 - 2025)
Larimar Therapeutics (LRMR) posted Amortizatization of Intangibles of -$157000.0 for Q4 2025, up 51.69% on a QoQ basis from -$325000.0 in Q3 2025, and up 86.72% year-over-year from -$84084.3 in Q4 2024.
Larimar Therapeutics (LRMR) Amortizatization of Intangibles (2015 - 2025) Analysis & Trends
Larimar Therapeutics' Amortizatization of Intangibles history runs 9 years deep, the most recent figure standing at -$157000.0 for Q4 2025.
- Quarterly Amortizatization of Intangibles rose 86.72% year-over-year to -$157000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.7 million (up 67.69% YoY) and the FY2025 annual result came in at -$1.7 million, up 67.69% from the prior year.
- Amortizatization of Intangibles was -$157000.0 for Q4 2025 at Larimar Therapeutics, up from -$325000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $3.1 million in Q4 2023 and bottomed at -$1.8 million in Q2 2024.
- A 5-year average of -$327555.6 and a median of -$393000.0 in 2025 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2022 — Amortizatization of Intangibles sank 35300.0% — and 2023, when it jumped 531.21%.
- Larimar Therapeutics' Amortizatization of Intangibles stood at -$2000.0 in 2021, then sank by 35300.0% to -$708000.0 in 2022, then soared by 531.21% to $3.1 million in 2023, then sank by 138.72% to -$1.2 million in 2024, then soared by 86.72% to -$157000.0 in 2025.
- Business Quant data shows LRMR's Amortizatization of Intangibles at -$157000.0 in Q4 2025, -$325000.0 in Q3 2025, and -$461000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Larimar Therapeutics | 37.00 Mn | -99.85 Mn | - | -157,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -157,000.00 |
| Dec 31, 2025 | -157,000.00 |
| Sep 30, 2025 | -325,000.00 |
| Sep 30, 2025 | -325,000.00 |
| Jun 30, 2025 | -461,000.00 |
| Jun 30, 2025 | -461,000.00 |
| Mar 31, 2025 | -755,000.00 |
| Mar 31, 2025 | -755,000.00 |
| Dec 31, 2024 | -1.18 Mn |
| Dec 31, 2024 | -1.18 Mn |
| Sep 30, 2024 | -1.71 Mn |
| Sep 30, 2024 | -1.71 Mn |
| Jun 30, 2024 | -1.78 Mn |
| Jun 30, 2024 | -1.78 Mn |
| Mar 31, 2024 | -583,000.00 |
| Mar 31, 2024 | -583,000.00 |
| Dec 31, 2023 | 3.05 Mn |
| Dec 31, 2023 | 3.05 Mn |
| Sep 30, 2023 | -565,000.00 |
| Sep 30, 2023 | -565,000.00 |